The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib.
Authors
Vishwanathan, KDickinson, P
So, K
Thomas, K
Chen, Y
De Castro Carpeño, J
Dingemans, A
Kim, H
Kim, J
Krebs, Matthew G
Yang, J
Bui, K
Weilert, D
Harvey, R
Affiliation
Quantitative Clinical Pharmacology, AstraZeneca, Waltham, MA, USAIssue Date
2018-01-30
Metadata
Show full item recordAbstract
We investigated the effects of a strong CYP3A4 inhibitor (itraconazole) or inducer (rifampicin) on the pharmacokinetics of the epidermal growth factor receptor kinase inhibitor osimertinib, in patients with advanced non-small cell lung cancer in two phase I, open-label, two-part clinical studies. Part one of both studies is reported.Citation
The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib. 2018, Br J Clin PharmacolJournal
British Journal of Clinical PharmacologyDOI
10.1111/bcp.13534PubMed ID
29381826Type
ArticleLanguage
enISSN
1365-2125ae974a485f413a2113503eed53cd6c53
10.1111/bcp.13534